FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362543670> ?p ?o ?g. }

• W4362543670 endingPage "5886" @default.
• W4362543670 startingPage "5886" @default.
• W4362543670 abstract "Abstract The impact of non-small cell lung cancer (NSCLC) tumor metabolism on the immune microenvironment is not well understood in the context of platinum resistance. We have identified and characterized crucial metabolic differences between cisplatin-resistant (CR) and cisplatin-sensitive (CS) NSCLC cells in which CR cells possessed higher indoleamine 2,3-dioxygenase-1 (IDO1) activity as determined by an increase in extracellular kynurenine concentration in vitro and in vivo. Utilizing in vitro co-culture models (n=6), we showed that IDO-mediated kynurenine production from CR cells suppressed natural killer group 2 member D (NKG2D) on natural killer (NK) and CD8+ T cells, but enhanced immunosuppressive regulatory T cell (Treg) and myeloid-derived suppressor cells (MDSC) populations. Utilizing syngeneic (n=7) and humanized (n=5) mouse models, mice with CR tumors exhibited a more highly immunosuppressive environment that blocked the antitumor immune response. Inhibition of IDO1 by the selective IDO1 inhibitor epacadostat (200 mg/kg P.O. once a day for 15 days) attenuated tumor growth in these CR tumor-bearing mice. Interestingly, we found an induction of tryptophan 2,3-dioxygenase-2 (TDO2) enzyme in epacadostat-treated mice. To overcome this compensatory effect induced by IDO1 inhibition, mice were treated with a novel IDO1/TDO2 dual inhibitor (AT-0174; Antido Therapeutics Pty Ltd, Melbourne, Australia) at 170 mg/kg P.O. once a day for 15 days. Dual inhibitors suppressed tumor growth to a greater degree than IDO1 inhibitors in CR conditions, and significantly enhanced immune effector populations as well as suppressed immunosuppressive Tregs and MDSC population in CR tumors. In addition, increased expression of programmed death-ligand 1 (PD-L1) was observed in CR cells, we assessed the effects of combination treatment of AT-0174 + anti-PD1 antibody. This combined therapy produced a profound anti-tumor effect in CR tumors and extended survival in mice. Our data support an increase in the therapeutic efficacy of blocking both IDO1/TDO2 in treating CR lung cancer by enhancing tumor immune surveillance. Thus, inhibiting the kynurenine pathway may be a more suitable therapeutic approach in a subgroup of lung cancer patients who failed platinum therapy and lead to improved outcomes in the treatment and management of NSCLC. Support by Dept. of Veterans. Citation Format: Sydney Spector, Chunjing Wu, George Theodore, Jonathan Dan Nguyen, Emily Kim, Ashley Garcia, Niramol Savaraj, Diane Lim, Lynn Feun, Medhi Wangpaichitr. Targeting IDO1 and TDO2 is crucial for the modulation of immune effector in platinum resistant non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 5886." @default.
• W4362543670 created "2023-04-06" @default.
• W4362543670 creator A5016502794 @default.
• W4362543670 creator A5017278215 @default.
• W4362543670 creator A5031308430 @default.
• W4362543670 creator A5037442981 @default.
• W4362543670 creator A5038264812 @default.
• W4362543670 creator A5056352637 @default.
• W4362543670 creator A5059946830 @default.
• W4362543670 creator A5071339563 @default.
• W4362543670 creator A5084747274 @default.
• W4362543670 creator A5087907162 @default.
• W4362543670 date "2023-04-04" @default.
• W4362543670 modified "2023-10-17" @default.
• W4362543670 title "Abstract 5886: Targeting IDO1 and TDO2 is crucial for the modulation of immune effector in platinum resistant non-small cell lung cancer" @default.
• W4362543670 doi "https://doi.org/10.1158/1538-7445.am2023-5886" @default.
• W4362543670 hasPublicationYear "2023" @default.
• W4362543670 type Work @default.
• W4362543670 citedByCount "0" @default.
• W4362543670 crossrefType "journal-article" @default.
• W4362543670 hasAuthorship W4362543670A5016502794 @default.
• W4362543670 hasAuthorship W4362543670A5017278215 @default.
• W4362543670 hasAuthorship W4362543670A5031308430 @default.
• W4362543670 hasAuthorship W4362543670A5037442981 @default.
• W4362543670 hasAuthorship W4362543670A5038264812 @default.
• W4362543670 hasAuthorship W4362543670A5056352637 @default.
• W4362543670 hasAuthorship W4362543670A5059946830 @default.
• W4362543670 hasAuthorship W4362543670A5071339563 @default.
• W4362543670 hasAuthorship W4362543670A5084747274 @default.
• W4362543670 hasAuthorship W4362543670A5087907162 @default.
• W4362543670 hasConcept C126322002 @default.
• W4362543670 hasConcept C150903083 @default.
• W4362543670 hasConcept C154317977 @default.
• W4362543670 hasConcept C167672396 @default.
• W4362543670 hasConcept C185592680 @default.
• W4362543670 hasConcept C202751555 @default.
• W4362543670 hasConcept C203014093 @default.
• W4362543670 hasConcept C207001950 @default.
• W4362543670 hasConcept C2776090121 @default.
• W4362543670 hasConcept C2776107976 @default.
• W4362543670 hasConcept C2776694085 @default.
• W4362543670 hasConcept C2776706248 @default.
• W4362543670 hasConcept C2777503454 @default.
• W4362543670 hasConcept C2778239845 @default.
• W4362543670 hasConcept C502942594 @default.
• W4362543670 hasConcept C515207424 @default.
• W4362543670 hasConcept C55493867 @default.
• W4362543670 hasConcept C71924100 @default.
• W4362543670 hasConcept C83478079 @default.
• W4362543670 hasConcept C86803240 @default.
• W4362543670 hasConcept C8891405 @default.
• W4362543670 hasConcept C98274493 @default.
• W4362543670 hasConceptScore W4362543670C126322002 @default.
• W4362543670 hasConceptScore W4362543670C150903083 @default.
• W4362543670 hasConceptScore W4362543670C154317977 @default.
• W4362543670 hasConceptScore W4362543670C167672396 @default.
• W4362543670 hasConceptScore W4362543670C185592680 @default.
• W4362543670 hasConceptScore W4362543670C202751555 @default.
• W4362543670 hasConceptScore W4362543670C203014093 @default.
• W4362543670 hasConceptScore W4362543670C207001950 @default.
• W4362543670 hasConceptScore W4362543670C2776090121 @default.
• W4362543670 hasConceptScore W4362543670C2776107976 @default.
• W4362543670 hasConceptScore W4362543670C2776694085 @default.
• W4362543670 hasConceptScore W4362543670C2776706248 @default.
• W4362543670 hasConceptScore W4362543670C2777503454 @default.
• W4362543670 hasConceptScore W4362543670C2778239845 @default.
• W4362543670 hasConceptScore W4362543670C502942594 @default.
• W4362543670 hasConceptScore W4362543670C515207424 @default.
• W4362543670 hasConceptScore W4362543670C55493867 @default.
• W4362543670 hasConceptScore W4362543670C71924100 @default.
• W4362543670 hasConceptScore W4362543670C83478079 @default.
• W4362543670 hasConceptScore W4362543670C86803240 @default.
• W4362543670 hasConceptScore W4362543670C8891405 @default.
• W4362543670 hasConceptScore W4362543670C98274493 @default.
• W4362543670 hasIssue "7_Supplement" @default.
• W4362543670 hasLocation W43625436701 @default.
• W4362543670 hasOpenAccess W4362543670 @default.
• W4362543670 hasPrimaryLocation W43625436701 @default.
• W4362543670 hasRelatedWork W2006425566 @default.
• W4362543670 hasRelatedWork W2115230511 @default.
• W4362543670 hasRelatedWork W2138864047 @default.
• W4362543670 hasRelatedWork W2180521141 @default.
• W4362543670 hasRelatedWork W2277096347 @default.
• W4362543670 hasRelatedWork W2407812582 @default.
• W4362543670 hasRelatedWork W3038084605 @default.
• W4362543670 hasRelatedWork W3165143150 @default.
• W4362543670 hasRelatedWork W4311529084 @default.
• W4362543670 hasRelatedWork W4320018381 @default.
• W4362543670 hasVolume "83" @default.
• W4362543670 isParatext "false" @default.
• W4362543670 isRetracted "false" @default.
• W4362543670 workType "article" @default.